UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
  

 
SCHEDULE 13G
 
  
 
Under the Securities Exchange Act of 1934
 
  
 
(Amendment No. 1)*
  

 
Seelos Therapeutics, Inc.
  
 
(Name of Issuer)
  

 
Common Stock, par value $0.001 per share
  
 
(Title of Class of Securities)
  

 
81577F406
  
 
(CUSIP Number)
  

 
September 30, 2024
  
 
(Date of Event which Requires Filing of this Statement)
  


Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
[ ]            Rule 13d-1(b)
[x]            Rule 13d-1(c)
[ ]            Rule 13d-1(d)
___________________________________
*  The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.
The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).


1
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
Lind Global Fund II LP
2
Check the Appropriate Box if a Member of a Group (See Instructions)
 
(a)            [ ]
 
(b)            [x]
3
SEC Use Only
4
Citizenship or Place of Organization.
 
Delaware

Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
5  Sole Voting Power
44,500
6  Shared Voting Power
 
0
7  Sole Dispositive Power
 
44,500
8  Shared Dispositive Power
 
0

9
Aggregate Amount Beneficially Owned by Each Reporting Person
 
44,500(1)
  
10
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
  
11
Percent of Class Represented by Amount in Row (9)*
 
9.9%(2)
  
12
Type of Reporting Person (See Instructions)
PN
  
(1) The reporting person’s ownership consists of (i) 3,026 shares of common stock, (ii) 17,372 warrants to purchase shares of common stock (the “A Warrants”), (iii) 17,372 warrants to purchase shares of common stock (the “B Warrants”), and (iv) 15,121 warrants to purchase shares of common stock (the “2029 Warrants,” together with the A Warrants and the B Warrants, the “Warrants”); however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership has been limited to 44,500 shares in the aggregate.
(2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.



1
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
Lind Global Partners II LLC
2
Check the Appropriate Box if a Member of a Group (See Instructions)
 
(a)            [ ]
 
(b)            [x]
3
SEC Use Only
4
Citizenship or Place of Organization.
 
Delaware

Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
5  Sole Voting Power
 
44,500
6  Shared Voting Power
 
0
7  Sole Dispositive Power
 
44,500
8  Shared Dispositive Power
 
0

9
Aggregate Amount Beneficially Owned by Each Reporting Person
 
44,500(1)
  
10
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
  
11
Percent of Class Represented by Amount in Row (9)*
 
9.9%(2)
  
12
Type of Reporting Person (See Instructions)
OO
  
(1) The reporting person’s ownership consists of (i) 3,026 shares of common stock, (ii) 17,372 A Warrants, (iii) 17,372 B Warrants, and (iv) 15,121 2029 Warrants; however, due to the exercise limitations of the Warrants, the reporting person’s beneficial ownership has been limited to 44,500 shares in the aggregate.
(2) Each of the Warrants includes a provision limiting the holder’s ability to exercise the Warrants if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.
1
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
Lind Global Asset Management V, LLC
2
Check the Appropriate Box if a Member of a Group (See Instructions)
 
(a)            [ ]
 
(b)            [x]
3
SEC Use Only
4
Citizenship or Place of Organization.
 
Delaware

Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
5  Sole Voting Power
 
412
6  Shared Voting Power
 
0
7  Sole Dispositive Power
 
412
8  Shared Dispositive Power
 
0

9
Aggregate Amount Beneficially Owned by Each Reporting Person
 
412(1)
  
10
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
  
11
Percent of Class Represented by Amount in Row (9)*
 
0.1%
  
12
Type of Reporting Person (See Instructions)
OO
  
(1) The reporting person’s ownership consists of 412 shares of common stock issuable to the reporting person pursuant to a convertible security entered into between Lind Global Asset Management V, LLC and Seelos Therapeutics, Inc. (the “Convertible Security”).

1
Names of Reporting Persons.
I.R.S. Identification Nos. of above persons (entities only)
 
Jeff Easton
2
Check the Appropriate Box if a Member of a Group (See Instructions)
 
(a)            [ ]
 
(b)            [x]
3
SEC Use Only
4
Citizenship or Place of Organization.
 
United States

Number
of Shares
Beneficially
Owned by
Each
Reporting
Person With
5  Sole Voting Power
 
44,500
6  Shared Voting Power
 
0
7  Sole Dispositive Power
 
44,500
8  Shared Dispositive Power
 
0

9
Aggregate Amount Beneficially Owned by Each Reporting Person
44,500(1)
  
10
Check if the Aggregate Amount in Row (9) Excludes Certain Shares (See Instructions)
 
  
11
Percent of Class Represented by Amount in Row (9)*
 
9.9%(2)
  
12
Type of Reporting Person (See Instructions)
 
IN
  
(1) The reporting person’s ownership consists of (i) 3,026 shares of common stock, (ii) 17,372 A Warrants, (iii) 17,372 B Warrants, (iv) 15,121 2029 Warrants and (v) 412 shares of common stock issuable to the reporting person pursuant to the Convertible Security; however, due to the exercise limitations of the Warrants and the conversion limitations on the Convertible Security, the reporting person’s beneficial ownership has been limited to 44,500 shares in the aggregate.
(2) The Warrants and the Convertible Security each include a provision limiting the holder’s ability to exercise the Warrants or convert the Convertible Security if such exercise would cause the holder to beneficially own greater than 9.99% of the Company.

Item 1.
(a)
Name of Issuer
 
 
Seelos Therapeutics, Inc.
(b)
Address of Issuer’s Principal Executive Offices
 
 
300 Park Avenue, 2nd Floor
New York, NY 10022
 

Item 2.
(a)
Name of Person Filing
 
 
This statement is filed by the following entities and individuals (collectively, referred to as the “Reporting Persons”):
 
•    Lind Global Fund II LP, a Delaware limited partnership;
•    Lind Global Partners II LLC, a Delaware limited liability company;
•    Lind Global Asset Management V, LLC; and
•    Jeff Easton, an individual and a citizen of the United States of America.
 
Lind Global Partners II LLC, the general partner of Lind Global Fund II LP, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP.
 
Jeff Easton, the managing member of Lind Global Partners II LLC and Lind Global Asset Management V, LLC, may be deemed to have sole voting and dispositive power with respect to the shares held by Lind Global Fund II LP and Lind Global Asset Management V, LLC, respectively.
 
(b)
Address of Principal Business Office or, if none, Residence
 
 
The address of the principal business office for each of the Reporting Persons is:
 
444 Madison Ave, Floor 41
New York, NY 10022
 
(c)
Citizenship
 
 
See Row 4 of cover page for each Reporting Person.
 
(d)
Title of Class of Securities
 
Common Stock, par value $0.001 per share
 
(e)
CUSIP Number
 
 
81577F406
Item 3.
If this statement is filed pursuant to §§240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
Not applicable.
Item 4.
Ownership
Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1.
(a)
Amount Beneficially Owned
 
 
 See Row 9 of cover page for each Reporting Person.
 
(b)
Percent of Class
 
 
See Row 11 of cover page for each Reporting Person.
 

(c)
Number of shares as to which such person has:
 
 
(i)
sole power to vote or to direct the vote
   

See Row 5 of cover page for each Reporting Person.
 
 
(ii)
shared power to vote or to direct the vote
   
 
See Row 6 of cover page for each Reporting Person.
 
 
(iii)
sole power to dispose or to direct the disposition of
   

See Row 7 of cover page for each Reporting Person.
 
 
(iv)
shared power to dispose or to direct the disposition of
   
 
See Row 8 of cover page for each Reporting Person.
 

Item 5.  Ownership of Five Percent or Less of a Class
If this statement is being filed to report the fact that as of the date hereof the reporting person has ceased to be the beneficial owner of more than five percent of the class of securities, check the following ☐.
Item 6.  Ownership of More than Five Percent on Behalf of Another Person
Not applicable.
Item 7.  Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on By the Parent Holding Company
Not applicable.
Item 8.
Identification and Classification of Members of the Group
Not applicable.
Item 9.
Notice of Dissolution of Group
Not Applicable.
Item 10.
Certification
By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.

Exhibits     Exhibit

99.1                  Joint Filing Agreement by and among the Reporting Persons.
SIGNATURE
 
After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.
 
November 14, 2024
 
LIND GLOBAL FUND II LP
   
By:
 
Lind Global Partners II LLC
 
 
its General Partner
   
By:
  
/s/ Jeff Easton
Name:
 
Jeff Easton
Title:
 
Managing Member
 
LIND GLOBAL PARTNERS II LLC
   
By:
 
/s/ Jeff Easton
Name:
 
Jeff Easton
Title:
 
Managing Member
     
LIND GLOBAL ASSET MANAGEMENT V, LLC
     
By:
  
/s/ Jeff Easton
Name:
  
Jeff Easton
Title:
  
Managing Member
 
JEFF EASTON
 
By:
 
/s/ Jeff Easton



Exhibit 99.1

JOINT FILING AGREEMENT
 
The undersigned hereby agree that a single Schedule 13G (or any amendment thereto) relating to the Common Stock, par value $0.001 per share, of Seelos Therapeutics, Inc. shall be filed on behalf of each of the undersigned and that this Agreement shall be filed as an exhibit to such Schedule 13G.
 
November 14, 2024
 
LIND GLOBAL FUND II LP
   
By:
 
Lind Global Partners II LLC
 
 
its General Partner
   
By:
  
/s/ Jeff Easton
Name:
 
Jeff Easton
Title:
 
Managing Member
 
LIND GLOBAL PARTNERS II LLC
   
By:
 
/s/ Jeff Easton
Name:
 
Jeff Easton
Title:
 
Managing Member
     
LIND GLOBAL ASSET MANAGEMENT V, LLC
     
By:
  
/s/ Jeff Easton
Name:
  
Jeff Easton
Title:
  
Managing Member
 
JEFF EASTON
 
By:
 
/s/ Jeff Easton



Seelos Therapeutics (QB) (USOTC:SEEL)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Seelos Therapeutics (QB) Charts.
Seelos Therapeutics (QB) (USOTC:SEEL)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Seelos Therapeutics (QB) Charts.